Insilico Medicine and SK Biopharmaceuticals Form AI-Powered Drug Discovery Collaboration for Neuroimmune CNS Disorders

Insilico Medicine (Insilico), a US-based clinical-stage drug discovery company, and SK Biopharmaceuticals, a South Korea-based biotechnology company, announced an R&D collaboration at the 2026 BIO International Convention (BIO 2026), occurring June 22-25 in San Diego. The deal pairs Insilico's generative artificial intelligence (AI)-driven drug discovery platform with SK Biopharmaceuticals' central nervous system (CNS) development and commercialization infrastructure. Under the deal, the partners will identify novel drug candidates for neuroimmune disorders of the CNS.¹

The agreement covers neuroinflammatory, neurodegenerative, and rare neurological indications, representing a therapeutic area characterized by significant unmet need and historically low clinical success rates.¹ The total potential deal value exceeds $2.5 billion, including development, regulatory, and commercial milestones, plus single-digit royalties on net sales.

"By combining Insilico's AI-powered drug discovery platform with SK Biopharmaceuticals' clinical development and US commercialization capabilities, we believe we can accelerate the discovery of innovative CNS therapies for patients," said Donghoon Lee, president and CEO of SK Biopharmaceuticals, in a company press release.¹

What are the financial terms and operational responsibilities under this collaboration?

Insilico will receive up to $18 million in upfront and near-term milestone payments, with total potential value exceeding $2.5 billion across preclinical, clinical, regulatory, and commercial milestones, plus single-digit royalties on commercialized products. Insilico will apply its Pharma.AI platform, which consists of target identification and validation, generative chemistry, and molecule optimization, to discover and optimize novel neuroimmune candidates.

SK Biopharmaceuticals will assume responsibility for late-stage development and commercialization, drawing on its established CNS infrastructure. The company’s cenobamate (Xcopri) is considered the first novel CNS drug independently developed and commercialized in the United States by a South Korean pharmaceutical company, according to SK Biopharmaceuticals.¹

Why do neuroimmune CNS disorders represent both a high-unmet-need and high-attrition drug discovery space?

Neuroimmune disorders, which encompass neuroinflammatory conditions, neurodegenerative diseases, and rare neurological disorders, impose a global disease burden compounded by complex, incompletely understood pathophysiology.² Phase 2 to approval success rates in CNS drug development have historically remained below 10%, based on challenges in target validation, blood-brain barrier penetration, and the absence of reliable translational biomarkers.³

These challenges pose a compelling application for AI-driven discovery platforms in CNS disorders that are capable of integrating multi-modal biological data more efficiently than conventional methods. Whether upstream AI efficiency gains translate into improved clinical success rates at scale have yet to be demonstrated.³

What is Insilico's Pharma.AI platform, and what preclinical track record supports its application here?

Insilico reported a target-to-preclinical candidate (PCC) timeline of 12 to 18 months compared to the industry-typical 2.5 to 4 years. The company said in its release that it has synthesized 60 to 200 molecules per program.¹ Since 2021, the company has nominated 31 PCCs, 13 of which have received investigational new drug application approval or clearance. Its most advanced program, INS018_055, a generative AI-discovered TRAF2 and NCK interacting kinase (TNIK) inhibitor for idiopathic pulmonary fibrosis, is in phase 2 trials and is considered among the first AI-generated candidates to reach mid-stage human testing.⁴

What limitations apply, and what disclosures would allow independent assessment of this collaboration?

No drug targets, disease indications, lead series, or preclinical data were disclosed at the time of announcement. The $2.5 billion figure represents a contingent maximum across multiple programs over many years, not necessarily near-term value. Independent benchmarking of Pharma.AI in CNS target classes, which present distinct biological complexity relative to fibrosis or oncology, is not available from public sources. Peer-reviewed outcome data from this collaboration would be essential to evaluating its clinical translation potential.⁵

References

1. Insilico Medicine. Insilico Medicine and SK Biopharmaceuticals achieved AI-powered drug discovery collaboration worth up to 2.5 billion for neuroimmune disorders. PR Newswire. Published June 22, 2026. Accessed June 22, 2026. https://www.prnewswire.com/news-releases/insilico-medicine-and-sk-biopharmaceuticals-achieved-ai-powered-drug-discovery-collaboration-worth-up-to-2-5-billion-for-neuroimmune-disorders-302806072.html
2. Ransohoff RM, Schafer D, Vincent A, Blachère NE, Bar-Or A. Neuroinflammation: ways in which the immune system affects the brain. Neurotherapeutics. 2015;12(4):896-909. doi:10.1007/s13311-015-0385-3
3. Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer's disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis. 2018;64(s1):S3-S22. doi:10.3233/JAD-179901
4. Ren, F., Aliper, A., Chen, J. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. 43, 63–75 (2025). doi.10.1038/s41587-024-02143-0
5. Schneider P, Walters WP, Plowright AT, et al. Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 2020;19(5):353-364. doi:10.1038/s41573-019-0050-3